IBDEI00N ; ; 01-AUG-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,1004,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1004,1,3,0)
;;=3^Hodgkin lymphoma, unspecified, unspecified site
;;^UTILITY(U,$J,358.3,1004,1,4,0)
;;=4^C81.90
;;^UTILITY(U,$J,358.3,1004,2)
;;=^5001451
;;^UTILITY(U,$J,358.3,1005,0)
;;=C82.69^^10^74^17
;;^UTILITY(U,$J,358.3,1005,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1005,1,3,0)
;;=3^Cutan folicl center lymphoma, extrnod and solid organ sites
;;^UTILITY(U,$J,358.3,1005,1,4,0)
;;=4^C82.69
;;^UTILITY(U,$J,358.3,1005,2)
;;=^5001530
;;^UTILITY(U,$J,358.3,1006,0)
;;=C82.60^^10^74^18
;;^UTILITY(U,$J,358.3,1006,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1006,1,3,0)
;;=3^Cutaneous follicle center lymphoma, unspecified site
;;^UTILITY(U,$J,358.3,1006,1,4,0)
;;=4^C82.60
;;^UTILITY(U,$J,358.3,1006,2)
;;=^5001521
;;^UTILITY(U,$J,358.3,1007,0)
;;=C82.49^^10^74^33
;;^UTILITY(U,$J,358.3,1007,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1007,1,3,0)
;;=3^Follicular lymphoma grade IIIb, extrnod and solid organ sites
;;^UTILITY(U,$J,358.3,1007,1,4,0)
;;=4^C82.49
;;^UTILITY(U,$J,358.3,1007,2)
;;=^5001510
;;^UTILITY(U,$J,358.3,1008,0)
;;=C82.40^^10^74^34
;;^UTILITY(U,$J,358.3,1008,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1008,1,3,0)
;;=3^Follicular lymphoma grade IIIb, unspecified site
;;^UTILITY(U,$J,358.3,1008,1,4,0)
;;=4^C82.40
;;^UTILITY(U,$J,358.3,1008,2)
;;=^5001501
;;^UTILITY(U,$J,358.3,1009,0)
;;=C82.19^^10^74^28
;;^UTILITY(U,$J,358.3,1009,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1009,1,3,0)
;;=3^Follicular lymphoma grade II, extrnod and solid organ sites
;;^UTILITY(U,$J,358.3,1009,1,4,0)
;;=4^C82.19
;;^UTILITY(U,$J,358.3,1009,2)
;;=^5001480
;;^UTILITY(U,$J,358.3,1010,0)
;;=C82.39^^10^74^31
;;^UTILITY(U,$J,358.3,1010,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1010,1,3,0)
;;=3^Follicular lymphoma grade IIIa, extrnod and solid organ sites
;;^UTILITY(U,$J,358.3,1010,1,4,0)
;;=4^C82.39
;;^UTILITY(U,$J,358.3,1010,2)
;;=^5001500
;;^UTILITY(U,$J,358.3,1011,0)
;;=C82.30^^10^74^32
;;^UTILITY(U,$J,358.3,1011,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1011,1,3,0)
;;=3^Follicular lymphoma grade IIIa, unspecified site
;;^UTILITY(U,$J,358.3,1011,1,4,0)
;;=4^C82.30
;;^UTILITY(U,$J,358.3,1011,2)
;;=^5001491
;;^UTILITY(U,$J,358.3,1012,0)
;;=C82.29^^10^74^25
;;^UTILITY(U,$J,358.3,1012,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1012,1,3,0)
;;=3^Follicular lymph grade III, unsp, extrnod and solid org sites
;;^UTILITY(U,$J,358.3,1012,1,4,0)
;;=4^C82.29
;;^UTILITY(U,$J,358.3,1012,2)
;;=^5001490
;;^UTILITY(U,$J,358.3,1013,0)
;;=C82.20^^10^74^30
;;^UTILITY(U,$J,358.3,1013,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1013,1,3,0)
;;=3^Follicular lymphoma grade III, unspecified, unspecified site
;;^UTILITY(U,$J,358.3,1013,1,4,0)
;;=4^C82.20
;;^UTILITY(U,$J,358.3,1013,2)
;;=^5001481
;;^UTILITY(U,$J,358.3,1014,0)
;;=C82.09^^10^74^26
;;^UTILITY(U,$J,358.3,1014,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1014,1,3,0)
;;=3^Follicular lymphoma grade I, extrnod and solid organ sites
;;^UTILITY(U,$J,358.3,1014,1,4,0)
;;=4^C82.09
;;^UTILITY(U,$J,358.3,1014,2)
;;=^5001470
;;^UTILITY(U,$J,358.3,1015,0)
;;=C82.10^^10^74^29
;;^UTILITY(U,$J,358.3,1015,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1015,1,3,0)
;;=3^Follicular lymphoma grade II, unspecified site
;;^UTILITY(U,$J,358.3,1015,1,4,0)
;;=4^C82.10
;;^UTILITY(U,$J,358.3,1015,2)
;;=^5001471
;;^UTILITY(U,$J,358.3,1016,0)
;;=C82.00^^10^74^27
;;^UTILITY(U,$J,358.3,1016,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1016,1,3,0)
;;=3^Follicular lymphoma grade I, unspecified site
;;^UTILITY(U,$J,358.3,1016,1,4,0)
;;=4^C82.00
;;^UTILITY(U,$J,358.3,1016,2)
;;=^5001461
;;^UTILITY(U,$J,358.3,1017,0)
;;=C82.90^^10^74^36
;;^UTILITY(U,$J,358.3,1017,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1017,1,3,0)
;;=3^Follicular lymphoma, unspecified, unspecified site
;;^UTILITY(U,$J,358.3,1017,1,4,0)
;;=4^C82.90
;;^UTILITY(U,$J,358.3,1017,2)
;;=^5001541
;;^UTILITY(U,$J,358.3,1018,0)
;;=C82.99^^10^74^35
;;^UTILITY(U,$J,358.3,1018,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1018,1,3,0)
;;=3^Follicular lymphoma, unsp, extranodal and solid organ sites
;;^UTILITY(U,$J,358.3,1018,1,4,0)
;;=4^C82.99
;;^UTILITY(U,$J,358.3,1018,2)
;;=^5001550
;;^UTILITY(U,$J,358.3,1019,0)
;;=C84.00^^10^74^60
;;^UTILITY(U,$J,358.3,1019,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1019,1,3,0)
;;=3^Mycosis fungoides, unspecified site
;;^UTILITY(U,$J,358.3,1019,1,4,0)
;;=4^C84.00
;;^UTILITY(U,$J,358.3,1019,2)
;;=^5001621
;;^UTILITY(U,$J,358.3,1020,0)
;;=C84.09^^10^74^59
;;^UTILITY(U,$J,358.3,1020,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1020,1,3,0)
;;=3^Mycosis fungoides, extranodal and solid organ sites
;;^UTILITY(U,$J,358.3,1020,1,4,0)
;;=4^C84.09
;;^UTILITY(U,$J,358.3,1020,2)
;;=^5001630
;;^UTILITY(U,$J,358.3,1021,0)
;;=C84.60^^10^74^8
;;^UTILITY(U,$J,358.3,1021,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1021,1,3,0)
;;=3^Anaplastic large cell lymphoma, ALK-positive, unsp site
;;^UTILITY(U,$J,358.3,1021,1,4,0)
;;=4^C84.60
;;^UTILITY(U,$J,358.3,1021,2)
;;=^5001651
;;^UTILITY(U,$J,358.3,1022,0)
;;=C84.69^^10^74^10
;;^UTILITY(U,$J,358.3,1022,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1022,1,3,0)
;;=3^Anaplstc lg cell lymph, ALK-pos, extrnod and solid org sites
;;^UTILITY(U,$J,358.3,1022,1,4,0)
;;=4^C84.69
;;^UTILITY(U,$J,358.3,1022,2)
;;=^5001660
;;^UTILITY(U,$J,358.3,1023,0)
;;=C84.70^^10^74^7
;;^UTILITY(U,$J,358.3,1023,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1023,1,3,0)
;;=3^Anaplastic large cell lymphoma, ALK-negative, unsp site
;;^UTILITY(U,$J,358.3,1023,1,4,0)
;;=4^C84.70
;;^UTILITY(U,$J,358.3,1023,2)
;;=^5001661
;;^UTILITY(U,$J,358.3,1024,0)
;;=C84.79^^10^74^9
;;^UTILITY(U,$J,358.3,1024,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1024,1,3,0)
;;=3^Anaplstc lg cell lymph, ALK-neg, extrnod and solid org sites
;;^UTILITY(U,$J,358.3,1024,1,4,0)
;;=4^C84.79
;;^UTILITY(U,$J,358.3,1024,2)
;;=^5001670
;;^UTILITY(U,$J,358.3,1025,0)
;;=C91.40^^10^74^37
;;^UTILITY(U,$J,358.3,1025,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1025,1,3,0)
;;=3^Hairy cell leukemia not having achieved remission
;;^UTILITY(U,$J,358.3,1025,1,4,0)
;;=4^C91.40
;;^UTILITY(U,$J,358.3,1025,2)
;;=^5001771
;;^UTILITY(U,$J,358.3,1026,0)
;;=C91.41^^10^74^39
;;^UTILITY(U,$J,358.3,1026,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1026,1,3,0)
;;=3^Hairy cell leukemia, in remission
;;^UTILITY(U,$J,358.3,1026,1,4,0)
;;=4^C91.41
;;^UTILITY(U,$J,358.3,1026,2)
;;=^5001772
;;^UTILITY(U,$J,358.3,1027,0)
;;=C91.42^^10^74^38
;;^UTILITY(U,$J,358.3,1027,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1027,1,3,0)
;;=3^Hairy cell leukemia, in relapse
;;^UTILITY(U,$J,358.3,1027,1,4,0)
;;=4^C91.42
;;^UTILITY(U,$J,358.3,1027,2)
;;=^5001773
;;^UTILITY(U,$J,358.3,1028,0)
;;=C96.4^^10^74^71
;;^UTILITY(U,$J,358.3,1028,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1028,1,3,0)
;;=3^Sarcoma of dendritic cells (accessory cells)
;;^UTILITY(U,$J,358.3,1028,1,4,0)
;;=4^C96.4
;;^UTILITY(U,$J,358.3,1028,2)
;;=^5001861
;;^UTILITY(U,$J,358.3,1029,0)
;;=C96.9^^10^74^50
;;^UTILITY(U,$J,358.3,1029,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1029,1,3,0)
;;=3^Malig neoplm of lymphoid, hematpoetc and rel tissue, unsp
;;^UTILITY(U,$J,358.3,1029,1,4,0)
;;=4^C96.9
;;^UTILITY(U,$J,358.3,1029,2)
;;=^5001864
;;^UTILITY(U,$J,358.3,1030,0)
;;=C90.00^^10^74^58
;;^UTILITY(U,$J,358.3,1030,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1030,1,3,0)
;;=3^Multiple myeloma not having achieved remission
;;^UTILITY(U,$J,358.3,1030,1,4,0)
;;=4^C90.00
;;^UTILITY(U,$J,358.3,1030,2)
;;=^5001752
;;^UTILITY(U,$J,358.3,1031,0)
;;=C90.01^^10^74^57
;;^UTILITY(U,$J,358.3,1031,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1031,1,3,0)
;;=3^Multiple myeloma in remission
;;^UTILITY(U,$J,358.3,1031,1,4,0)
;;=4^C90.01
;;^UTILITY(U,$J,358.3,1031,2)
;;=^267515
;;^UTILITY(U,$J,358.3,1032,0)
;;=C90.02^^10^74^56
;;^UTILITY(U,$J,358.3,1032,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1032,1,3,0)
;;=3^Multiple myeloma in relapse
;;^UTILITY(U,$J,358.3,1032,1,4,0)
;;=4^C90.02
;;^UTILITY(U,$J,358.3,1032,2)
;;=^5001753
;;^UTILITY(U,$J,358.3,1033,0)
;;=C91.00^^10^74^1
;;^UTILITY(U,$J,358.3,1033,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1033,1,3,0)
;;=3^Acute lymphoblastic leukemia not having achieved remission
;;^UTILITY(U,$J,358.3,1033,1,4,0)
;;=4^C91.00
;;^UTILITY(U,$J,358.3,1033,2)
;;=^5001762
;;^UTILITY(U,$J,358.3,1034,0)
;;=C91.01^^10^74^3
;;^UTILITY(U,$J,358.3,1034,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1034,1,3,0)
;;=3^Acute lymphoblastic leukemia, in remission
;;^UTILITY(U,$J,358.3,1034,1,4,0)
;;=4^C91.01
;;^UTILITY(U,$J,358.3,1034,2)
;;=^5001763
;;^UTILITY(U,$J,358.3,1035,0)
;;=C91.02^^10^74^2
;;^UTILITY(U,$J,358.3,1035,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1035,1,3,0)
;;=3^Acute lymphoblastic leukemia, in relapse
;;^UTILITY(U,$J,358.3,1035,1,4,0)
;;=4^C91.02
;;^UTILITY(U,$J,358.3,1035,2)
;;=^5001764
;;^UTILITY(U,$J,358.3,1036,0)
;;=C91.10^^10^74^13
;;^UTILITY(U,$J,358.3,1036,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1036,1,3,0)
;;=3^Chronic lymphocytic leuk of B-cell type not achieve remis
;;^UTILITY(U,$J,358.3,1036,1,4,0)
;;=4^C91.10
;;^UTILITY(U,$J,358.3,1036,2)
;;=^5001765
;;^UTILITY(U,$J,358.3,1037,0)
;;=C91.11^^10^74^14
;;^UTILITY(U,$J,358.3,1037,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1037,1,3,0)
;;=3^Chronic lymphocytic leukemia of B-cell type in remission
;;^UTILITY(U,$J,358.3,1037,1,4,0)
;;=4^C91.11
;;^UTILITY(U,$J,358.3,1037,2)
;;=^5001766
;;^UTILITY(U,$J,358.3,1038,0)
;;=C91.12^^10^74^15
;;^UTILITY(U,$J,358.3,1038,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1038,1,3,0)
;;=3^Chronic lymphocytic leukemia of B-cell type in relapse
;;^UTILITY(U,$J,358.3,1038,1,4,0)
;;=4^C91.12
;;^UTILITY(U,$J,358.3,1038,2)
;;=^5001767
;;^UTILITY(U,$J,358.3,1039,0)
;;=D47.1^^10^74^16
;;^UTILITY(U,$J,358.3,1039,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1039,1,3,0)
;;=3^Chronic myeloproliferative disease
;;^UTILITY(U,$J,358.3,1039,1,4,0)
;;=4^D47.1
;;^UTILITY(U,$J,358.3,1039,2)
;;=^5002256
;;^UTILITY(U,$J,358.3,1040,0)
;;=C94.42^^10^74^5
;;^UTILITY(U,$J,358.3,1040,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1040,1,3,0)
;;=3^Acute panmyelosis with myelofibrosis, in relapse
;;^UTILITY(U,$J,358.3,1040,1,4,0)
;;=4^C94.42
;;^UTILITY(U,$J,358.3,1040,2)
;;=^5001845
;;^UTILITY(U,$J,358.3,1041,0)
;;=C94.41^^10^74^6
;;^UTILITY(U,$J,358.3,1041,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1041,1,3,0)
;;=3^Acute panmyelosis with myelofibrosis, in remission
;;^UTILITY(U,$J,358.3,1041,1,4,0)
;;=4^C94.41
;;^UTILITY(U,$J,358.3,1041,2)
;;=^5001844
;;^UTILITY(U,$J,358.3,1042,0)
;;=C94.40^^10^74^4
;;^UTILITY(U,$J,358.3,1042,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1042,1,3,0)
;;=3^Acute panmyelosis w myelofibrosis not achieve remission
;;^UTILITY(U,$J,358.3,1042,1,4,0)
;;=4^C94.40
;;^UTILITY(U,$J,358.3,1042,2)
;;=^5001843
;;^UTILITY(U,$J,358.3,1043,0)
;;=D47.2^^10^74^55
;;^UTILITY(U,$J,358.3,1043,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1043,1,3,0)
;;=3^Monoclonal gammopathy
;;^UTILITY(U,$J,358.3,1043,1,4,0)
;;=4^D47.2
;;^UTILITY(U,$J,358.3,1043,2)
;;=^5002257
;;^UTILITY(U,$J,358.3,1044,0)
;;=C88.0^^10^74^76
;;^UTILITY(U,$J,358.3,1044,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1044,1,3,0)
;;=3^Waldenstrom macroglobulinemia
;;^UTILITY(U,$J,358.3,1044,1,4,0)
;;=4^C88.0
;;^UTILITY(U,$J,358.3,1044,2)
;;=^5001748
;;^UTILITY(U,$J,358.3,1045,0)
;;=C81.70^^10^74^41
;;^UTILITY(U,$J,358.3,1045,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1045,1,3,0)
;;=3^Hodgkin Lymphoma,Classical,Unspec Site NEC
;;^UTILITY(U,$J,358.3,1045,1,4,0)
;;=4^C81.70
;;^UTILITY(U,$J,358.3,1045,2)
;;=^5001441
;;^UTILITY(U,$J,358.3,1046,0)
;;=C81.79^^10^74^40
;;^UTILITY(U,$J,358.3,1046,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1046,1,3,0)
;;=3^Hodgkin Lymphoma,Classical,Extrnod/Solid Organ Sites NEC
;;^UTILITY(U,$J,358.3,1046,1,4,0)
;;=4^C81.79
;;^UTILITY(U,$J,358.3,1046,2)
;;=^5001450
;;^UTILITY(U,$J,358.3,1047,0)
;;=C82.50^^10^74^20
;;^UTILITY(U,$J,358.3,1047,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1047,1,3,0)
;;=3^Diffuse Follicle Center Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,1047,1,4,0)
;;=4^C82.50
;;^UTILITY(U,$J,358.3,1047,2)
;;=^5001511
;;^UTILITY(U,$J,358.3,1048,0)
;;=C82.59^^10^74^19
;;^UTILITY(U,$J,358.3,1048,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1048,1,3,0)
;;=3^Diffuse Follicle Center Lymphoma,Extrnod/Solid Organ Sites
;;^UTILITY(U,$J,358.3,1048,1,4,0)
;;=4^C82.59
;;^UTILITY(U,$J,358.3,1048,2)
;;=^5001520
;;^UTILITY(U,$J,358.3,1049,0)
;;=C82.80^^10^74^24
;;^UTILITY(U,$J,358.3,1049,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1049,1,3,0)
;;=3^Follicular Lymphoma,Unspec Site NEC
;;^UTILITY(U,$J,358.3,1049,1,4,0)
;;=4^C82.80
;;^UTILITY(U,$J,358.3,1049,2)
;;=^5001531
;;^UTILITY(U,$J,358.3,1050,0)
;;=C82.89^^10^74^23
;;^UTILITY(U,$J,358.3,1050,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1050,1,3,0)
;;=3^Follicular Lymphoma,Extrnod/Solid Organ Sites NEC
;;^UTILITY(U,$J,358.3,1050,1,4,0)
;;=4^C82.89
;;^UTILITY(U,$J,358.3,1050,2)
;;=^5001540
;;^UTILITY(U,$J,358.3,1051,0)
;;=C83.00^^10^74^75
;;^UTILITY(U,$J,358.3,1051,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1051,1,3,0)
;;=3^Small Cell B-Cell Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,1051,1,4,0)
;;=4^C83.00
;;^UTILITY(U,$J,358.3,1051,2)
;;=^5001551
;;^UTILITY(U,$J,358.3,1052,0)
;;=C83.09^^10^74^74
;;^UTILITY(U,$J,358.3,1052,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1052,1,3,0)
;;=3^Small Cell B-Cell Lymphoma,Extrnod/Solid Organ Sites
;;^UTILITY(U,$J,358.3,1052,1,4,0)
;;=4^C83.09
;;^UTILITY(U,$J,358.3,1052,2)
;;=^5001560
;;^UTILITY(U,$J,358.3,1053,0)
;;=C83.30^^10^74^21
;;^UTILITY(U,$J,358.3,1053,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1053,1,3,0)
;;=3^Diffuse Large B-Cell Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,1053,1,4,0)
;;=4^C83.30
;;^UTILITY(U,$J,358.3,1053,2)
;;=^5001571
;;^UTILITY(U,$J,358.3,1054,0)
;;=C83.80^^10^74^66
;;^UTILITY(U,$J,358.3,1054,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1054,1,3,0)
;;=3^Non-Follicular Lymphoma,Unspec Site NEC
;;^UTILITY(U,$J,358.3,1054,1,4,0)
;;=4^C83.80
;;^UTILITY(U,$J,358.3,1054,2)
;;=^5001601
;;^UTILITY(U,$J,358.3,1055,0)
;;=C83.89^^10^74^65
;;^UTILITY(U,$J,358.3,1055,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1055,1,3,0)
;;=3^Non-Follicular Lymphoma,Extrnod/Solid Organ Sites
;;^UTILITY(U,$J,358.3,1055,1,4,0)
;;=4^C83.89
;;^UTILITY(U,$J,358.3,1055,2)
;;=^5001610
;;^UTILITY(U,$J,358.3,1056,0)
;;=C83.90^^10^74^68
;;^UTILITY(U,$J,358.3,1056,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1056,1,3,0)
;;=3^Non-Follicular Lymphoma,Unspec,Unspec Site
;;^UTILITY(U,$J,358.3,1056,1,4,0)
;;=4^C83.90
;;^UTILITY(U,$J,358.3,1056,2)
;;=^5001611
;;^UTILITY(U,$J,358.3,1057,0)
;;=C83.99^^10^74^67
;;^UTILITY(U,$J,358.3,1057,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1057,1,3,0)
;;=3^Non-Follicular Lymphoma,Unspec,Extranod/Solid Organ Sites
;;^UTILITY(U,$J,358.3,1057,1,4,0)
;;=4^C83.99
;;^UTILITY(U,$J,358.3,1057,2)
;;=^5001620
;;^UTILITY(U,$J,358.3,1058,0)
;;=C84.10^^10^74^73
;;^UTILITY(U,$J,358.3,1058,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1058,1,3,0)
;;=3^Sezary Disease,Unspec Site
;;^UTILITY(U,$J,358.3,1058,1,4,0)
;;=4^C84.10
;;^UTILITY(U,$J,358.3,1058,2)
;;=^5001631
;;^UTILITY(U,$J,358.3,1059,0)
;;=C84.19^^10^74^72
;;^UTILITY(U,$J,358.3,1059,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1059,1,3,0)
;;=3^Sezary Disease,Extrnod/Solid Organ Sites
;;^UTILITY(U,$J,358.3,1059,1,4,0)
;;=4^C84.19
;;^UTILITY(U,$J,358.3,1059,2)
;;=^5001640
;;^UTILITY(U,$J,358.3,1060,0)
;;=C84.40^^10^74^70
;;^UTILITY(U,$J,358.3,1060,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1060,1,3,0)
;;=3^Peripheral T-Cell Lymphoma,Unspec Site NEC
;;^UTILITY(U,$J,358.3,1060,1,4,0)
;;=4^C84.40
;;^UTILITY(U,$J,358.3,1060,2)
;;=^5001641
;;^UTILITY(U,$J,358.3,1061,0)
;;=C84.49^^10^74^69
;;^UTILITY(U,$J,358.3,1061,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1061,1,3,0)
;;=3^Peripheral T-Cell Lymphoma,Extrnod/Solid Organ Sites NEC
;;^UTILITY(U,$J,358.3,1061,1,4,0)
;;=4^C84.49
;;^UTILITY(U,$J,358.3,1061,2)
;;=^5001650
;;^UTILITY(U,$J,358.3,1062,0)
;;=C77.0^^10^75^14
;;^UTILITY(U,$J,358.3,1062,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1062,1,3,0)
;;=3^Secondary malignant neoplasm of nodes of head, face and neck
;;^UTILITY(U,$J,358.3,1062,1,4,0)
;;=4^C77.0
;;^UTILITY(U,$J,358.3,1062,2)
;;=^5001329
;;^UTILITY(U,$J,358.3,1063,0)
;;=C77.1^^10^75^9
;;^UTILITY(U,$J,358.3,1063,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1063,1,3,0)
;;=3^Secondary malignant neoplasm of intrathorac nodes
;;^UTILITY(U,$J,358.3,1063,1,4,0)
;;=4^C77.1
;;^UTILITY(U,$J,358.3,1063,2)
;;=^267315
;;^UTILITY(U,$J,358.3,1064,0)
;;=C77.2^^10^75^7
;;^UTILITY(U,$J,358.3,1064,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1064,1,3,0)
;;=3^Secondary malignant neoplasm of intra-abd nodes
;;^UTILITY(U,$J,358.3,1064,1,4,0)
;;=4^C77.2
;;^UTILITY(U,$J,358.3,1064,2)
;;=^267316
;;^UTILITY(U,$J,358.3,1065,0)
;;=C77.3^^10^75^1
;;^UTILITY(U,$J,358.3,1065,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1065,1,3,0)
;;=3^Secondary malignant neoplasm of axilla and upper limb nodes
;;^UTILITY(U,$J,358.3,1065,1,4,0)
;;=4^C77.3
;;^UTILITY(U,$J,358.3,1065,2)
;;=^5001330
;;^UTILITY(U,$J,358.3,1066,0)
;;=C77.4^^10^75^6
;;^UTILITY(U,$J,358.3,1066,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1066,1,3,0)
;;=3^Secondary malignant neoplasm of inguinal and lower limb nodes
;;^UTILITY(U,$J,358.3,1066,1,4,0)
;;=4^C77.4
;;^UTILITY(U,$J,358.3,1066,2)
;;=^5001331
;;^UTILITY(U,$J,358.3,1067,0)
;;=C77.8^^10^75^15
;;^UTILITY(U,$J,358.3,1067,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1067,1,3,0)
;;=3^Secondary malignant neoplasm of nodes of multiple regions
;;^UTILITY(U,$J,358.3,1067,1,4,0)
;;=4^C77.8
;;^UTILITY(U,$J,358.3,1067,2)
;;=^5001332
;;^UTILITY(U,$J,358.3,1068,0)
;;=C77.9^^10^75^13
;;^UTILITY(U,$J,358.3,1068,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1068,1,3,0)
;;=3^Secondary malignant neoplasm of lymph node, unsp
;;^UTILITY(U,$J,358.3,1068,1,4,0)
;;=4^C77.9
;;^UTILITY(U,$J,358.3,1068,2)
;;=^5001333
;;^UTILITY(U,$J,358.3,1069,0)
;;=C78.01^^10^75^18
;;^UTILITY(U,$J,358.3,1069,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1069,1,3,0)
;;=3^Secondary malignant neoplasm of right lung
;;^UTILITY(U,$J,358.3,1069,1,4,0)
;;=4^C78.01
;;^UTILITY(U,$J,358.3,1069,2)
;;=^5001335
;;^UTILITY(U,$J,358.3,1070,0)
;;=C78.02^^10^75^11
;;^UTILITY(U,$J,358.3,1070,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI00N 19750 printed Apr 09, 2024@21:13:44 Page 2
IBDEI00N ; ; 01-AUG-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,1004,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,1004,1,3,0)
+4 ;;=3^Hodgkin lymphoma, unspecified, unspecified site
+5 ;;^UTILITY(U,$J,358.3,1004,1,4,0)
+6 ;;=4^C81.90
+7 ;;^UTILITY(U,$J,358.3,1004,2)
+8 ;;=^5001451
+9 ;;^UTILITY(U,$J,358.3,1005,0)
+10 ;;=C82.69^^10^74^17
+11 ;;^UTILITY(U,$J,358.3,1005,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,1005,1,3,0)
+14 ;;=3^Cutan folicl center lymphoma, extrnod and solid organ sites
+15 ;;^UTILITY(U,$J,358.3,1005,1,4,0)
+16 ;;=4^C82.69
+17 ;;^UTILITY(U,$J,358.3,1005,2)
+18 ;;=^5001530
+19 ;;^UTILITY(U,$J,358.3,1006,0)
+20 ;;=C82.60^^10^74^18
+21 ;;^UTILITY(U,$J,358.3,1006,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,1006,1,3,0)
+24 ;;=3^Cutaneous follicle center lymphoma, unspecified site
+25 ;;^UTILITY(U,$J,358.3,1006,1,4,0)
+26 ;;=4^C82.60
+27 ;;^UTILITY(U,$J,358.3,1006,2)
+28 ;;=^5001521
+29 ;;^UTILITY(U,$J,358.3,1007,0)
+30 ;;=C82.49^^10^74^33
+31 ;;^UTILITY(U,$J,358.3,1007,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,1007,1,3,0)
+34 ;;=3^Follicular lymphoma grade IIIb, extrnod and solid organ sites
+35 ;;^UTILITY(U,$J,358.3,1007,1,4,0)
+36 ;;=4^C82.49
+37 ;;^UTILITY(U,$J,358.3,1007,2)
+38 ;;=^5001510
+39 ;;^UTILITY(U,$J,358.3,1008,0)
+40 ;;=C82.40^^10^74^34
+41 ;;^UTILITY(U,$J,358.3,1008,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,1008,1,3,0)
+44 ;;=3^Follicular lymphoma grade IIIb, unspecified site
+45 ;;^UTILITY(U,$J,358.3,1008,1,4,0)
+46 ;;=4^C82.40
+47 ;;^UTILITY(U,$J,358.3,1008,2)
+48 ;;=^5001501
+49 ;;^UTILITY(U,$J,358.3,1009,0)
+50 ;;=C82.19^^10^74^28
+51 ;;^UTILITY(U,$J,358.3,1009,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,1009,1,3,0)
+54 ;;=3^Follicular lymphoma grade II, extrnod and solid organ sites
+55 ;;^UTILITY(U,$J,358.3,1009,1,4,0)
+56 ;;=4^C82.19
+57 ;;^UTILITY(U,$J,358.3,1009,2)
+58 ;;=^5001480
+59 ;;^UTILITY(U,$J,358.3,1010,0)
+60 ;;=C82.39^^10^74^31
+61 ;;^UTILITY(U,$J,358.3,1010,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,1010,1,3,0)
+64 ;;=3^Follicular lymphoma grade IIIa, extrnod and solid organ sites
+65 ;;^UTILITY(U,$J,358.3,1010,1,4,0)
+66 ;;=4^C82.39
+67 ;;^UTILITY(U,$J,358.3,1010,2)
+68 ;;=^5001500
+69 ;;^UTILITY(U,$J,358.3,1011,0)
+70 ;;=C82.30^^10^74^32
+71 ;;^UTILITY(U,$J,358.3,1011,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,1011,1,3,0)
+74 ;;=3^Follicular lymphoma grade IIIa, unspecified site
+75 ;;^UTILITY(U,$J,358.3,1011,1,4,0)
+76 ;;=4^C82.30
+77 ;;^UTILITY(U,$J,358.3,1011,2)
+78 ;;=^5001491
+79 ;;^UTILITY(U,$J,358.3,1012,0)
+80 ;;=C82.29^^10^74^25
+81 ;;^UTILITY(U,$J,358.3,1012,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,1012,1,3,0)
+84 ;;=3^Follicular lymph grade III, unsp, extrnod and solid org sites
+85 ;;^UTILITY(U,$J,358.3,1012,1,4,0)
+86 ;;=4^C82.29
+87 ;;^UTILITY(U,$J,358.3,1012,2)
+88 ;;=^5001490
+89 ;;^UTILITY(U,$J,358.3,1013,0)
+90 ;;=C82.20^^10^74^30
+91 ;;^UTILITY(U,$J,358.3,1013,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,1013,1,3,0)
+94 ;;=3^Follicular lymphoma grade III, unspecified, unspecified site
+95 ;;^UTILITY(U,$J,358.3,1013,1,4,0)
+96 ;;=4^C82.20
+97 ;;^UTILITY(U,$J,358.3,1013,2)
+98 ;;=^5001481
+99 ;;^UTILITY(U,$J,358.3,1014,0)
+100 ;;=C82.09^^10^74^26
+101 ;;^UTILITY(U,$J,358.3,1014,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,1014,1,3,0)
+104 ;;=3^Follicular lymphoma grade I, extrnod and solid organ sites
+105 ;;^UTILITY(U,$J,358.3,1014,1,4,0)
+106 ;;=4^C82.09
+107 ;;^UTILITY(U,$J,358.3,1014,2)
+108 ;;=^5001470
+109 ;;^UTILITY(U,$J,358.3,1015,0)
+110 ;;=C82.10^^10^74^29
+111 ;;^UTILITY(U,$J,358.3,1015,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,1015,1,3,0)
+114 ;;=3^Follicular lymphoma grade II, unspecified site
+115 ;;^UTILITY(U,$J,358.3,1015,1,4,0)
+116 ;;=4^C82.10
+117 ;;^UTILITY(U,$J,358.3,1015,2)
+118 ;;=^5001471
+119 ;;^UTILITY(U,$J,358.3,1016,0)
+120 ;;=C82.00^^10^74^27
+121 ;;^UTILITY(U,$J,358.3,1016,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,1016,1,3,0)
+124 ;;=3^Follicular lymphoma grade I, unspecified site
+125 ;;^UTILITY(U,$J,358.3,1016,1,4,0)
+126 ;;=4^C82.00
+127 ;;^UTILITY(U,$J,358.3,1016,2)
+128 ;;=^5001461
+129 ;;^UTILITY(U,$J,358.3,1017,0)
+130 ;;=C82.90^^10^74^36
+131 ;;^UTILITY(U,$J,358.3,1017,1,0)
+132 ;;=^358.31IA^4^2
+133 ;;^UTILITY(U,$J,358.3,1017,1,3,0)
+134 ;;=3^Follicular lymphoma, unspecified, unspecified site
+135 ;;^UTILITY(U,$J,358.3,1017,1,4,0)
+136 ;;=4^C82.90
+137 ;;^UTILITY(U,$J,358.3,1017,2)
+138 ;;=^5001541
+139 ;;^UTILITY(U,$J,358.3,1018,0)
+140 ;;=C82.99^^10^74^35
+141 ;;^UTILITY(U,$J,358.3,1018,1,0)
+142 ;;=^358.31IA^4^2
+143 ;;^UTILITY(U,$J,358.3,1018,1,3,0)
+144 ;;=3^Follicular lymphoma, unsp, extranodal and solid organ sites
+145 ;;^UTILITY(U,$J,358.3,1018,1,4,0)
+146 ;;=4^C82.99
+147 ;;^UTILITY(U,$J,358.3,1018,2)
+148 ;;=^5001550
+149 ;;^UTILITY(U,$J,358.3,1019,0)
+150 ;;=C84.00^^10^74^60
+151 ;;^UTILITY(U,$J,358.3,1019,1,0)
+152 ;;=^358.31IA^4^2
+153 ;;^UTILITY(U,$J,358.3,1019,1,3,0)
+154 ;;=3^Mycosis fungoides, unspecified site
+155 ;;^UTILITY(U,$J,358.3,1019,1,4,0)
+156 ;;=4^C84.00
+157 ;;^UTILITY(U,$J,358.3,1019,2)
+158 ;;=^5001621
+159 ;;^UTILITY(U,$J,358.3,1020,0)
+160 ;;=C84.09^^10^74^59
+161 ;;^UTILITY(U,$J,358.3,1020,1,0)
+162 ;;=^358.31IA^4^2
+163 ;;^UTILITY(U,$J,358.3,1020,1,3,0)
+164 ;;=3^Mycosis fungoides, extranodal and solid organ sites
+165 ;;^UTILITY(U,$J,358.3,1020,1,4,0)
+166 ;;=4^C84.09
+167 ;;^UTILITY(U,$J,358.3,1020,2)
+168 ;;=^5001630
+169 ;;^UTILITY(U,$J,358.3,1021,0)
+170 ;;=C84.60^^10^74^8
+171 ;;^UTILITY(U,$J,358.3,1021,1,0)
+172 ;;=^358.31IA^4^2
+173 ;;^UTILITY(U,$J,358.3,1021,1,3,0)
+174 ;;=3^Anaplastic large cell lymphoma, ALK-positive, unsp site
+175 ;;^UTILITY(U,$J,358.3,1021,1,4,0)
+176 ;;=4^C84.60
+177 ;;^UTILITY(U,$J,358.3,1021,2)
+178 ;;=^5001651
+179 ;;^UTILITY(U,$J,358.3,1022,0)
+180 ;;=C84.69^^10^74^10
+181 ;;^UTILITY(U,$J,358.3,1022,1,0)
+182 ;;=^358.31IA^4^2
+183 ;;^UTILITY(U,$J,358.3,1022,1,3,0)
+184 ;;=3^Anaplstc lg cell lymph, ALK-pos, extrnod and solid org sites
+185 ;;^UTILITY(U,$J,358.3,1022,1,4,0)
+186 ;;=4^C84.69
+187 ;;^UTILITY(U,$J,358.3,1022,2)
+188 ;;=^5001660
+189 ;;^UTILITY(U,$J,358.3,1023,0)
+190 ;;=C84.70^^10^74^7
+191 ;;^UTILITY(U,$J,358.3,1023,1,0)
+192 ;;=^358.31IA^4^2
+193 ;;^UTILITY(U,$J,358.3,1023,1,3,0)
+194 ;;=3^Anaplastic large cell lymphoma, ALK-negative, unsp site
+195 ;;^UTILITY(U,$J,358.3,1023,1,4,0)
+196 ;;=4^C84.70
+197 ;;^UTILITY(U,$J,358.3,1023,2)
+198 ;;=^5001661
+199 ;;^UTILITY(U,$J,358.3,1024,0)
+200 ;;=C84.79^^10^74^9
+201 ;;^UTILITY(U,$J,358.3,1024,1,0)
+202 ;;=^358.31IA^4^2
+203 ;;^UTILITY(U,$J,358.3,1024,1,3,0)
+204 ;;=3^Anaplstc lg cell lymph, ALK-neg, extrnod and solid org sites
+205 ;;^UTILITY(U,$J,358.3,1024,1,4,0)
+206 ;;=4^C84.79
+207 ;;^UTILITY(U,$J,358.3,1024,2)
+208 ;;=^5001670
+209 ;;^UTILITY(U,$J,358.3,1025,0)
+210 ;;=C91.40^^10^74^37
+211 ;;^UTILITY(U,$J,358.3,1025,1,0)
+212 ;;=^358.31IA^4^2
+213 ;;^UTILITY(U,$J,358.3,1025,1,3,0)
+214 ;;=3^Hairy cell leukemia not having achieved remission
+215 ;;^UTILITY(U,$J,358.3,1025,1,4,0)
+216 ;;=4^C91.40
+217 ;;^UTILITY(U,$J,358.3,1025,2)
+218 ;;=^5001771
+219 ;;^UTILITY(U,$J,358.3,1026,0)
+220 ;;=C91.41^^10^74^39
+221 ;;^UTILITY(U,$J,358.3,1026,1,0)
+222 ;;=^358.31IA^4^2
+223 ;;^UTILITY(U,$J,358.3,1026,1,3,0)
+224 ;;=3^Hairy cell leukemia, in remission
+225 ;;^UTILITY(U,$J,358.3,1026,1,4,0)
+226 ;;=4^C91.41
+227 ;;^UTILITY(U,$J,358.3,1026,2)
+228 ;;=^5001772
+229 ;;^UTILITY(U,$J,358.3,1027,0)
+230 ;;=C91.42^^10^74^38
+231 ;;^UTILITY(U,$J,358.3,1027,1,0)
+232 ;;=^358.31IA^4^2
+233 ;;^UTILITY(U,$J,358.3,1027,1,3,0)
+234 ;;=3^Hairy cell leukemia, in relapse
+235 ;;^UTILITY(U,$J,358.3,1027,1,4,0)
+236 ;;=4^C91.42
+237 ;;^UTILITY(U,$J,358.3,1027,2)
+238 ;;=^5001773
+239 ;;^UTILITY(U,$J,358.3,1028,0)
+240 ;;=C96.4^^10^74^71
+241 ;;^UTILITY(U,$J,358.3,1028,1,0)
+242 ;;=^358.31IA^4^2
+243 ;;^UTILITY(U,$J,358.3,1028,1,3,0)
+244 ;;=3^Sarcoma of dendritic cells (accessory cells)
+245 ;;^UTILITY(U,$J,358.3,1028,1,4,0)
+246 ;;=4^C96.4
+247 ;;^UTILITY(U,$J,358.3,1028,2)
+248 ;;=^5001861
+249 ;;^UTILITY(U,$J,358.3,1029,0)
+250 ;;=C96.9^^10^74^50
+251 ;;^UTILITY(U,$J,358.3,1029,1,0)
+252 ;;=^358.31IA^4^2
+253 ;;^UTILITY(U,$J,358.3,1029,1,3,0)
+254 ;;=3^Malig neoplm of lymphoid, hematpoetc and rel tissue, unsp
+255 ;;^UTILITY(U,$J,358.3,1029,1,4,0)
+256 ;;=4^C96.9
+257 ;;^UTILITY(U,$J,358.3,1029,2)
+258 ;;=^5001864
+259 ;;^UTILITY(U,$J,358.3,1030,0)
+260 ;;=C90.00^^10^74^58
+261 ;;^UTILITY(U,$J,358.3,1030,1,0)
+262 ;;=^358.31IA^4^2
+263 ;;^UTILITY(U,$J,358.3,1030,1,3,0)
+264 ;;=3^Multiple myeloma not having achieved remission
+265 ;;^UTILITY(U,$J,358.3,1030,1,4,0)
+266 ;;=4^C90.00
+267 ;;^UTILITY(U,$J,358.3,1030,2)
+268 ;;=^5001752
+269 ;;^UTILITY(U,$J,358.3,1031,0)
+270 ;;=C90.01^^10^74^57
+271 ;;^UTILITY(U,$J,358.3,1031,1,0)
+272 ;;=^358.31IA^4^2
+273 ;;^UTILITY(U,$J,358.3,1031,1,3,0)
+274 ;;=3^Multiple myeloma in remission
+275 ;;^UTILITY(U,$J,358.3,1031,1,4,0)
+276 ;;=4^C90.01
+277 ;;^UTILITY(U,$J,358.3,1031,2)
+278 ;;=^267515
+279 ;;^UTILITY(U,$J,358.3,1032,0)
+280 ;;=C90.02^^10^74^56
+281 ;;^UTILITY(U,$J,358.3,1032,1,0)
+282 ;;=^358.31IA^4^2
+283 ;;^UTILITY(U,$J,358.3,1032,1,3,0)
+284 ;;=3^Multiple myeloma in relapse
+285 ;;^UTILITY(U,$J,358.3,1032,1,4,0)
+286 ;;=4^C90.02
+287 ;;^UTILITY(U,$J,358.3,1032,2)
+288 ;;=^5001753
+289 ;;^UTILITY(U,$J,358.3,1033,0)
+290 ;;=C91.00^^10^74^1
+291 ;;^UTILITY(U,$J,358.3,1033,1,0)
+292 ;;=^358.31IA^4^2
+293 ;;^UTILITY(U,$J,358.3,1033,1,3,0)
+294 ;;=3^Acute lymphoblastic leukemia not having achieved remission
+295 ;;^UTILITY(U,$J,358.3,1033,1,4,0)
+296 ;;=4^C91.00
+297 ;;^UTILITY(U,$J,358.3,1033,2)
+298 ;;=^5001762
+299 ;;^UTILITY(U,$J,358.3,1034,0)
+300 ;;=C91.01^^10^74^3
+301 ;;^UTILITY(U,$J,358.3,1034,1,0)
+302 ;;=^358.31IA^4^2
+303 ;;^UTILITY(U,$J,358.3,1034,1,3,0)
+304 ;;=3^Acute lymphoblastic leukemia, in remission
+305 ;;^UTILITY(U,$J,358.3,1034,1,4,0)
+306 ;;=4^C91.01
+307 ;;^UTILITY(U,$J,358.3,1034,2)
+308 ;;=^5001763
+309 ;;^UTILITY(U,$J,358.3,1035,0)
+310 ;;=C91.02^^10^74^2
+311 ;;^UTILITY(U,$J,358.3,1035,1,0)
+312 ;;=^358.31IA^4^2
+313 ;;^UTILITY(U,$J,358.3,1035,1,3,0)
+314 ;;=3^Acute lymphoblastic leukemia, in relapse
+315 ;;^UTILITY(U,$J,358.3,1035,1,4,0)
+316 ;;=4^C91.02
+317 ;;^UTILITY(U,$J,358.3,1035,2)
+318 ;;=^5001764
+319 ;;^UTILITY(U,$J,358.3,1036,0)
+320 ;;=C91.10^^10^74^13
+321 ;;^UTILITY(U,$J,358.3,1036,1,0)
+322 ;;=^358.31IA^4^2
+323 ;;^UTILITY(U,$J,358.3,1036,1,3,0)
+324 ;;=3^Chronic lymphocytic leuk of B-cell type not achieve remis
+325 ;;^UTILITY(U,$J,358.3,1036,1,4,0)
+326 ;;=4^C91.10
+327 ;;^UTILITY(U,$J,358.3,1036,2)
+328 ;;=^5001765
+329 ;;^UTILITY(U,$J,358.3,1037,0)
+330 ;;=C91.11^^10^74^14
+331 ;;^UTILITY(U,$J,358.3,1037,1,0)
+332 ;;=^358.31IA^4^2
+333 ;;^UTILITY(U,$J,358.3,1037,1,3,0)
+334 ;;=3^Chronic lymphocytic leukemia of B-cell type in remission
+335 ;;^UTILITY(U,$J,358.3,1037,1,4,0)
+336 ;;=4^C91.11
+337 ;;^UTILITY(U,$J,358.3,1037,2)
+338 ;;=^5001766
+339 ;;^UTILITY(U,$J,358.3,1038,0)
+340 ;;=C91.12^^10^74^15
+341 ;;^UTILITY(U,$J,358.3,1038,1,0)
+342 ;;=^358.31IA^4^2
+343 ;;^UTILITY(U,$J,358.3,1038,1,3,0)
+344 ;;=3^Chronic lymphocytic leukemia of B-cell type in relapse
+345 ;;^UTILITY(U,$J,358.3,1038,1,4,0)
+346 ;;=4^C91.12
+347 ;;^UTILITY(U,$J,358.3,1038,2)
+348 ;;=^5001767
+349 ;;^UTILITY(U,$J,358.3,1039,0)
+350 ;;=D47.1^^10^74^16
+351 ;;^UTILITY(U,$J,358.3,1039,1,0)
+352 ;;=^358.31IA^4^2
+353 ;;^UTILITY(U,$J,358.3,1039,1,3,0)
+354 ;;=3^Chronic myeloproliferative disease
+355 ;;^UTILITY(U,$J,358.3,1039,1,4,0)
+356 ;;=4^D47.1
+357 ;;^UTILITY(U,$J,358.3,1039,2)
+358 ;;=^5002256
+359 ;;^UTILITY(U,$J,358.3,1040,0)
+360 ;;=C94.42^^10^74^5
+361 ;;^UTILITY(U,$J,358.3,1040,1,0)
+362 ;;=^358.31IA^4^2
+363 ;;^UTILITY(U,$J,358.3,1040,1,3,0)
+364 ;;=3^Acute panmyelosis with myelofibrosis, in relapse
+365 ;;^UTILITY(U,$J,358.3,1040,1,4,0)
+366 ;;=4^C94.42
+367 ;;^UTILITY(U,$J,358.3,1040,2)
+368 ;;=^5001845
+369 ;;^UTILITY(U,$J,358.3,1041,0)
+370 ;;=C94.41^^10^74^6
+371 ;;^UTILITY(U,$J,358.3,1041,1,0)
+372 ;;=^358.31IA^4^2
+373 ;;^UTILITY(U,$J,358.3,1041,1,3,0)
+374 ;;=3^Acute panmyelosis with myelofibrosis, in remission
+375 ;;^UTILITY(U,$J,358.3,1041,1,4,0)
+376 ;;=4^C94.41
+377 ;;^UTILITY(U,$J,358.3,1041,2)
+378 ;;=^5001844
+379 ;;^UTILITY(U,$J,358.3,1042,0)
+380 ;;=C94.40^^10^74^4
+381 ;;^UTILITY(U,$J,358.3,1042,1,0)
+382 ;;=^358.31IA^4^2
+383 ;;^UTILITY(U,$J,358.3,1042,1,3,0)
+384 ;;=3^Acute panmyelosis w myelofibrosis not achieve remission
+385 ;;^UTILITY(U,$J,358.3,1042,1,4,0)
+386 ;;=4^C94.40
+387 ;;^UTILITY(U,$J,358.3,1042,2)
+388 ;;=^5001843
+389 ;;^UTILITY(U,$J,358.3,1043,0)
+390 ;;=D47.2^^10^74^55
+391 ;;^UTILITY(U,$J,358.3,1043,1,0)
+392 ;;=^358.31IA^4^2
+393 ;;^UTILITY(U,$J,358.3,1043,1,3,0)
+394 ;;=3^Monoclonal gammopathy
+395 ;;^UTILITY(U,$J,358.3,1043,1,4,0)
+396 ;;=4^D47.2
+397 ;;^UTILITY(U,$J,358.3,1043,2)
+398 ;;=^5002257
+399 ;;^UTILITY(U,$J,358.3,1044,0)
+400 ;;=C88.0^^10^74^76
+401 ;;^UTILITY(U,$J,358.3,1044,1,0)
+402 ;;=^358.31IA^4^2
+403 ;;^UTILITY(U,$J,358.3,1044,1,3,0)
+404 ;;=3^Waldenstrom macroglobulinemia
+405 ;;^UTILITY(U,$J,358.3,1044,1,4,0)
+406 ;;=4^C88.0
+407 ;;^UTILITY(U,$J,358.3,1044,2)
+408 ;;=^5001748
+409 ;;^UTILITY(U,$J,358.3,1045,0)
+410 ;;=C81.70^^10^74^41
+411 ;;^UTILITY(U,$J,358.3,1045,1,0)
+412 ;;=^358.31IA^4^2
+413 ;;^UTILITY(U,$J,358.3,1045,1,3,0)
+414 ;;=3^Hodgkin Lymphoma,Classical,Unspec Site NEC
+415 ;;^UTILITY(U,$J,358.3,1045,1,4,0)
+416 ;;=4^C81.70
+417 ;;^UTILITY(U,$J,358.3,1045,2)
+418 ;;=^5001441
+419 ;;^UTILITY(U,$J,358.3,1046,0)
+420 ;;=C81.79^^10^74^40
+421 ;;^UTILITY(U,$J,358.3,1046,1,0)
+422 ;;=^358.31IA^4^2
+423 ;;^UTILITY(U,$J,358.3,1046,1,3,0)
+424 ;;=3^Hodgkin Lymphoma,Classical,Extrnod/Solid Organ Sites NEC
+425 ;;^UTILITY(U,$J,358.3,1046,1,4,0)
+426 ;;=4^C81.79
+427 ;;^UTILITY(U,$J,358.3,1046,2)
+428 ;;=^5001450
+429 ;;^UTILITY(U,$J,358.3,1047,0)
+430 ;;=C82.50^^10^74^20
+431 ;;^UTILITY(U,$J,358.3,1047,1,0)
+432 ;;=^358.31IA^4^2
+433 ;;^UTILITY(U,$J,358.3,1047,1,3,0)
+434 ;;=3^Diffuse Follicle Center Lymphoma,Unspec Site
+435 ;;^UTILITY(U,$J,358.3,1047,1,4,0)
+436 ;;=4^C82.50
+437 ;;^UTILITY(U,$J,358.3,1047,2)
+438 ;;=^5001511
+439 ;;^UTILITY(U,$J,358.3,1048,0)
+440 ;;=C82.59^^10^74^19
+441 ;;^UTILITY(U,$J,358.3,1048,1,0)
+442 ;;=^358.31IA^4^2
+443 ;;^UTILITY(U,$J,358.3,1048,1,3,0)
+444 ;;=3^Diffuse Follicle Center Lymphoma,Extrnod/Solid Organ Sites
+445 ;;^UTILITY(U,$J,358.3,1048,1,4,0)
+446 ;;=4^C82.59
+447 ;;^UTILITY(U,$J,358.3,1048,2)
+448 ;;=^5001520
+449 ;;^UTILITY(U,$J,358.3,1049,0)
+450 ;;=C82.80^^10^74^24
+451 ;;^UTILITY(U,$J,358.3,1049,1,0)
+452 ;;=^358.31IA^4^2
+453 ;;^UTILITY(U,$J,358.3,1049,1,3,0)
+454 ;;=3^Follicular Lymphoma,Unspec Site NEC
+455 ;;^UTILITY(U,$J,358.3,1049,1,4,0)
+456 ;;=4^C82.80
+457 ;;^UTILITY(U,$J,358.3,1049,2)
+458 ;;=^5001531
+459 ;;^UTILITY(U,$J,358.3,1050,0)
+460 ;;=C82.89^^10^74^23
+461 ;;^UTILITY(U,$J,358.3,1050,1,0)
+462 ;;=^358.31IA^4^2
+463 ;;^UTILITY(U,$J,358.3,1050,1,3,0)
+464 ;;=3^Follicular Lymphoma,Extrnod/Solid Organ Sites NEC
+465 ;;^UTILITY(U,$J,358.3,1050,1,4,0)
+466 ;;=4^C82.89
+467 ;;^UTILITY(U,$J,358.3,1050,2)
+468 ;;=^5001540
+469 ;;^UTILITY(U,$J,358.3,1051,0)
+470 ;;=C83.00^^10^74^75
+471 ;;^UTILITY(U,$J,358.3,1051,1,0)
+472 ;;=^358.31IA^4^2
+473 ;;^UTILITY(U,$J,358.3,1051,1,3,0)
+474 ;;=3^Small Cell B-Cell Lymphoma,Unspec Site
+475 ;;^UTILITY(U,$J,358.3,1051,1,4,0)
+476 ;;=4^C83.00
+477 ;;^UTILITY(U,$J,358.3,1051,2)
+478 ;;=^5001551
+479 ;;^UTILITY(U,$J,358.3,1052,0)
+480 ;;=C83.09^^10^74^74
+481 ;;^UTILITY(U,$J,358.3,1052,1,0)
+482 ;;=^358.31IA^4^2
+483 ;;^UTILITY(U,$J,358.3,1052,1,3,0)
+484 ;;=3^Small Cell B-Cell Lymphoma,Extrnod/Solid Organ Sites
+485 ;;^UTILITY(U,$J,358.3,1052,1,4,0)
+486 ;;=4^C83.09
+487 ;;^UTILITY(U,$J,358.3,1052,2)
+488 ;;=^5001560
+489 ;;^UTILITY(U,$J,358.3,1053,0)
+490 ;;=C83.30^^10^74^21
+491 ;;^UTILITY(U,$J,358.3,1053,1,0)
+492 ;;=^358.31IA^4^2
+493 ;;^UTILITY(U,$J,358.3,1053,1,3,0)
+494 ;;=3^Diffuse Large B-Cell Lymphoma,Unspec Site
+495 ;;^UTILITY(U,$J,358.3,1053,1,4,0)
+496 ;;=4^C83.30
+497 ;;^UTILITY(U,$J,358.3,1053,2)
+498 ;;=^5001571
+499 ;;^UTILITY(U,$J,358.3,1054,0)
+500 ;;=C83.80^^10^74^66
+501 ;;^UTILITY(U,$J,358.3,1054,1,0)
+502 ;;=^358.31IA^4^2
+503 ;;^UTILITY(U,$J,358.3,1054,1,3,0)
+504 ;;=3^Non-Follicular Lymphoma,Unspec Site NEC
+505 ;;^UTILITY(U,$J,358.3,1054,1,4,0)
+506 ;;=4^C83.80
+507 ;;^UTILITY(U,$J,358.3,1054,2)
+508 ;;=^5001601
+509 ;;^UTILITY(U,$J,358.3,1055,0)
+510 ;;=C83.89^^10^74^65
+511 ;;^UTILITY(U,$J,358.3,1055,1,0)
+512 ;;=^358.31IA^4^2
+513 ;;^UTILITY(U,$J,358.3,1055,1,3,0)
+514 ;;=3^Non-Follicular Lymphoma,Extrnod/Solid Organ Sites
+515 ;;^UTILITY(U,$J,358.3,1055,1,4,0)
+516 ;;=4^C83.89
+517 ;;^UTILITY(U,$J,358.3,1055,2)
+518 ;;=^5001610
+519 ;;^UTILITY(U,$J,358.3,1056,0)
+520 ;;=C83.90^^10^74^68
+521 ;;^UTILITY(U,$J,358.3,1056,1,0)
+522 ;;=^358.31IA^4^2
+523 ;;^UTILITY(U,$J,358.3,1056,1,3,0)
+524 ;;=3^Non-Follicular Lymphoma,Unspec,Unspec Site
+525 ;;^UTILITY(U,$J,358.3,1056,1,4,0)
+526 ;;=4^C83.90
+527 ;;^UTILITY(U,$J,358.3,1056,2)
+528 ;;=^5001611
+529 ;;^UTILITY(U,$J,358.3,1057,0)
+530 ;;=C83.99^^10^74^67
+531 ;;^UTILITY(U,$J,358.3,1057,1,0)
+532 ;;=^358.31IA^4^2
+533 ;;^UTILITY(U,$J,358.3,1057,1,3,0)
+534 ;;=3^Non-Follicular Lymphoma,Unspec,Extranod/Solid Organ Sites
+535 ;;^UTILITY(U,$J,358.3,1057,1,4,0)
+536 ;;=4^C83.99
+537 ;;^UTILITY(U,$J,358.3,1057,2)
+538 ;;=^5001620
+539 ;;^UTILITY(U,$J,358.3,1058,0)
+540 ;;=C84.10^^10^74^73
+541 ;;^UTILITY(U,$J,358.3,1058,1,0)
+542 ;;=^358.31IA^4^2
+543 ;;^UTILITY(U,$J,358.3,1058,1,3,0)
+544 ;;=3^Sezary Disease,Unspec Site
+545 ;;^UTILITY(U,$J,358.3,1058,1,4,0)
+546 ;;=4^C84.10
+547 ;;^UTILITY(U,$J,358.3,1058,2)
+548 ;;=^5001631
+549 ;;^UTILITY(U,$J,358.3,1059,0)
+550 ;;=C84.19^^10^74^72
+551 ;;^UTILITY(U,$J,358.3,1059,1,0)
+552 ;;=^358.31IA^4^2
+553 ;;^UTILITY(U,$J,358.3,1059,1,3,0)
+554 ;;=3^Sezary Disease,Extrnod/Solid Organ Sites
+555 ;;^UTILITY(U,$J,358.3,1059,1,4,0)
+556 ;;=4^C84.19
+557 ;;^UTILITY(U,$J,358.3,1059,2)
+558 ;;=^5001640
+559 ;;^UTILITY(U,$J,358.3,1060,0)
+560 ;;=C84.40^^10^74^70
+561 ;;^UTILITY(U,$J,358.3,1060,1,0)
+562 ;;=^358.31IA^4^2
+563 ;;^UTILITY(U,$J,358.3,1060,1,3,0)
+564 ;;=3^Peripheral T-Cell Lymphoma,Unspec Site NEC
+565 ;;^UTILITY(U,$J,358.3,1060,1,4,0)
+566 ;;=4^C84.40
+567 ;;^UTILITY(U,$J,358.3,1060,2)
+568 ;;=^5001641
+569 ;;^UTILITY(U,$J,358.3,1061,0)
+570 ;;=C84.49^^10^74^69
+571 ;;^UTILITY(U,$J,358.3,1061,1,0)
+572 ;;=^358.31IA^4^2
+573 ;;^UTILITY(U,$J,358.3,1061,1,3,0)
+574 ;;=3^Peripheral T-Cell Lymphoma,Extrnod/Solid Organ Sites NEC
+575 ;;^UTILITY(U,$J,358.3,1061,1,4,0)
+576 ;;=4^C84.49
+577 ;;^UTILITY(U,$J,358.3,1061,2)
+578 ;;=^5001650
+579 ;;^UTILITY(U,$J,358.3,1062,0)
+580 ;;=C77.0^^10^75^14
+581 ;;^UTILITY(U,$J,358.3,1062,1,0)
+582 ;;=^358.31IA^4^2
+583 ;;^UTILITY(U,$J,358.3,1062,1,3,0)
+584 ;;=3^Secondary malignant neoplasm of nodes of head, face and neck
+585 ;;^UTILITY(U,$J,358.3,1062,1,4,0)
+586 ;;=4^C77.0
+587 ;;^UTILITY(U,$J,358.3,1062,2)
+588 ;;=^5001329
+589 ;;^UTILITY(U,$J,358.3,1063,0)
+590 ;;=C77.1^^10^75^9
+591 ;;^UTILITY(U,$J,358.3,1063,1,0)
+592 ;;=^358.31IA^4^2
+593 ;;^UTILITY(U,$J,358.3,1063,1,3,0)
+594 ;;=3^Secondary malignant neoplasm of intrathorac nodes
+595 ;;^UTILITY(U,$J,358.3,1063,1,4,0)
+596 ;;=4^C77.1
+597 ;;^UTILITY(U,$J,358.3,1063,2)
+598 ;;=^267315
+599 ;;^UTILITY(U,$J,358.3,1064,0)
+600 ;;=C77.2^^10^75^7
+601 ;;^UTILITY(U,$J,358.3,1064,1,0)
+602 ;;=^358.31IA^4^2
+603 ;;^UTILITY(U,$J,358.3,1064,1,3,0)
+604 ;;=3^Secondary malignant neoplasm of intra-abd nodes
+605 ;;^UTILITY(U,$J,358.3,1064,1,4,0)
+606 ;;=4^C77.2
+607 ;;^UTILITY(U,$J,358.3,1064,2)
+608 ;;=^267316
+609 ;;^UTILITY(U,$J,358.3,1065,0)
+610 ;;=C77.3^^10^75^1
+611 ;;^UTILITY(U,$J,358.3,1065,1,0)
+612 ;;=^358.31IA^4^2
+613 ;;^UTILITY(U,$J,358.3,1065,1,3,0)
+614 ;;=3^Secondary malignant neoplasm of axilla and upper limb nodes
+615 ;;^UTILITY(U,$J,358.3,1065,1,4,0)
+616 ;;=4^C77.3
+617 ;;^UTILITY(U,$J,358.3,1065,2)
+618 ;;=^5001330
+619 ;;^UTILITY(U,$J,358.3,1066,0)
+620 ;;=C77.4^^10^75^6
+621 ;;^UTILITY(U,$J,358.3,1066,1,0)
+622 ;;=^358.31IA^4^2
+623 ;;^UTILITY(U,$J,358.3,1066,1,3,0)
+624 ;;=3^Secondary malignant neoplasm of inguinal and lower limb nodes
+625 ;;^UTILITY(U,$J,358.3,1066,1,4,0)
+626 ;;=4^C77.4
+627 ;;^UTILITY(U,$J,358.3,1066,2)
+628 ;;=^5001331
+629 ;;^UTILITY(U,$J,358.3,1067,0)
+630 ;;=C77.8^^10^75^15
+631 ;;^UTILITY(U,$J,358.3,1067,1,0)
+632 ;;=^358.31IA^4^2
+633 ;;^UTILITY(U,$J,358.3,1067,1,3,0)
+634 ;;=3^Secondary malignant neoplasm of nodes of multiple regions
+635 ;;^UTILITY(U,$J,358.3,1067,1,4,0)
+636 ;;=4^C77.8
+637 ;;^UTILITY(U,$J,358.3,1067,2)
+638 ;;=^5001332
+639 ;;^UTILITY(U,$J,358.3,1068,0)
+640 ;;=C77.9^^10^75^13
+641 ;;^UTILITY(U,$J,358.3,1068,1,0)
+642 ;;=^358.31IA^4^2
+643 ;;^UTILITY(U,$J,358.3,1068,1,3,0)
+644 ;;=3^Secondary malignant neoplasm of lymph node, unsp
+645 ;;^UTILITY(U,$J,358.3,1068,1,4,0)
+646 ;;=4^C77.9
+647 ;;^UTILITY(U,$J,358.3,1068,2)
+648 ;;=^5001333
+649 ;;^UTILITY(U,$J,358.3,1069,0)
+650 ;;=C78.01^^10^75^18
+651 ;;^UTILITY(U,$J,358.3,1069,1,0)
+652 ;;=^358.31IA^4^2
+653 ;;^UTILITY(U,$J,358.3,1069,1,3,0)
+654 ;;=3^Secondary malignant neoplasm of right lung
+655 ;;^UTILITY(U,$J,358.3,1069,1,4,0)
+656 ;;=4^C78.01
+657 ;;^UTILITY(U,$J,358.3,1069,2)
+658 ;;=^5001335
+659 ;;^UTILITY(U,$J,358.3,1070,0)
+660 ;;=C78.02^^10^75^11
+661 ;;^UTILITY(U,$J,358.3,1070,1,0)
+662 ;;=^358.31IA^4^2
